Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany

European Journal of Clinical Pharmacology
Verena BergkWalter E Haefeli

Abstract

To determine drug interaction information requirements in general practice with respect to both content and mode of presentation. In a mail survey among 2,000 general practitioners in south-west Germany, we collected information on risk evaluation of drug interactions and combinations of concern, usage of and satisfaction with the current information sources, desirable content and mode of future presentation and demographic variables. Categorical variables were compared using chi2 test. Trends were analysed with Cochran-Armitage test and determinants of literature usage with logistic regression. Response rate was 60.8%. The majority of general practitioners considered drug interactions a risk factor in prescribing (88.6%). For 18.2% of the drug combinations most frequently indicated as interacting, there was no published evidence of a clinically relevant interaction. More than half of the participants were dissatisfied with the information on severity, mechanism, and dose adjustment currently available in their sources. In particular, non-interacting alternatives were thought to be lacking (86.9%). Users of drug interaction software more frequently retrieved drug interaction information than non-users [odds ratio (OR) 1.95; 95%...Continue Reading

References

Jul 5, 1995·JAMA : the Journal of the American Medical Association·D W BatesR Hallisey
Feb 1, 1997·Annals of Emergency Medicine·W H MullenK R Olson
Oct 30, 1998·JAMA : the Journal of the American Medical Association·D W BatesD L Seger
Feb 9, 2000·Pharmacology & Therapeutics·A CorsiniF Bernini
Mar 8, 2000·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·D L Borzekowski, A F Poussaint
Apr 20, 2001·Clinical Pharmacology and Therapeutics·H HalkinB B Malkin
Oct 18, 2002·Journal of Clinical Pharmacy and Therapeutics·D MagnusA J Avery
Jan 25, 2003·Clinical Pharmacology and Therapeutics·Anil Rajpal, Marcus M Reidenberg
Apr 4, 2003·JAMA : the Journal of the American Medical Association·David N JuurlinkDonald A Redelmeier
Aug 20, 2003·Journal of the American Medical Informatics Association : JAMIA·David W BatesBlackford Middleton
Oct 9, 2003·Scandinavian Journal of Primary Health Care·Lars BjerrumJakob Kragstrup
Nov 26, 2003·Archives of Internal Medicine·Saul N WeingartRussell S Phillips

❮ Previous
Next ❯

Citations

Dec 16, 2004·European Journal of Clinical Pharmacology·Meret Martin-FacklamWalter E Haefeli
Oct 7, 2006·European Journal of Clinical Pharmacology·R QuinzlerW E Haefeli
Jan 12, 2007·European Journal of Clinical Pharmacology·Jörg IndermitteKurt E Hersberger
Mar 26, 2009·European Journal of Clinical Pharmacology·Thilo BertscheWalter E Haefeli
Sep 12, 2008·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·Frédéric MilleMarie-Christine Jaulent
Dec 7, 2013·European Journal of Clinical Pharmacology·Annemieke Floor-SchreuderingPeter A G M De Smet
Mar 16, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Olesya I ZorinaStefan Russmann
Jun 10, 2009·Pharmacoepidemiology and Drug Safety·Michel WensingJoachim Szecsenyi
Mar 4, 2011·Journal of Clinical Pharmacy and Therapeutics·T-M Hu, W L Hayton
Apr 21, 2012·Pharmacoepidemiology and Drug Safety·Olesya I ZorinaStefan Russmann
Feb 12, 2010·BMC Health Services Research·Oyvind A BjertnaesGeir Bukholm
Feb 12, 2015·International Journal of Medical Informatics·Marine L AnderssonBirgit Eiermann
Nov 1, 2016·European Journal of Clinical Pharmacology·Giok Qin NgHui Ting Chng
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·John E MurphyGrant H Skrepnek
Jul 15, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Annemieke Floor-SchreuderingMarcel L Bouvy
Dec 17, 2011·The Medical Journal of Australia·Kitty H YuAmanda Fraser
Oct 24, 2009·The Medical Journal of Australia·Bryan W Tan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.